HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


NPD StriVectin report

This article was originally published in The Rose Sheet

Executive Summary

StriVectin-SD sales in U.S. department stores were $30 mil. during the first five months of 2004, though fewer than 5% of women are aware of the anti-aging and stretch mark cream, and only 12% of those own it, NPD Group reports in "Beyond Botox: Understanding the StriVectin-SD Consumer," released July 19. Klein-Becker's StriVectin originally launched in health food stores as a stretch mark treatment, but approximately 75% of buyers use the product to fight facial lines and wrinkles, market research firm says. Since its department store debut last May, StriVectin "has become an important player in the prestige skin care industry," NPD notes, adding the formula "has managed to surpass blockbuster prestige skin care products in terms of dollar volume"...

You may also be interested in...

Is StriVectin Better Than Botox? Not Without NDA Approval, FDA Says

Klein-Becker's signature statement for StriVectin-SD anti-aging cream - "Better than Botox?" - constitutes a structure/function claim that would require the product to be regulated as a drug, the agency states in a 1warning letter recently posted on its Web site

The Quality Lowdown: On Redeploying Inspectors, API Suppliers Thanks To Coronavirus

US investigators fan out to non-China inspection priorities and Secretary Azar talks supply management; warning letters hit record keeping, investigations and basic GMP compliance.

Mallinckrodt's Opioid Resolution Through Generic Unit Bankruptcy May Be 'Test Case'

Mallinckrodt to pay $1.6bn and place its generics unit in bankruptcy under agreement in principle for US global settlement; six states are not on board, including New York, whose suit is still set to go to trial March 20.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts